Barclays PLC Has $1.39 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Barclays PLC grew its holdings in SI-BONE, Inc. (NASDAQ:SIBN) by 2.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 99,212 shares of the company’s stock after acquiring an additional 2,589 shares during the period. Barclays PLC owned 0.24% of SI-BONE worth $1,391,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Mainstream Capital Management LLC bought a new position in SI-BONE in the 4th quarter worth $53,000. R Squared Ltd acquired a new stake in shares of SI-BONE during the 4th quarter valued at about $73,000. KLP Kapitalforvaltning AS bought a new stake in shares of SI-BONE in the 4th quarter valued at approximately $97,000. Proficio Capital Partners LLC bought a new stake in SI-BONE in the fourth quarter valued at $155,000. Finally, AlphaQuest LLC increased its position in shares of SI-BONE by 13,950.6% during the 4th quarter. AlphaQuest LLC now owns 11,662 shares of the company’s stock worth $164,000 after purchasing an additional 11,579 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. The trade was a 1.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Anthony J. Recupero sold 3,311 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now directly owns 284,555 shares in the company, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,112 shares of company stock worth $101,275. Company insiders own 3.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $22.00 price target (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Needham & Company LLC increased their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE currently has an average rating of “Buy” and a consensus price target of $24.40.

SI-BONE Stock Performance

Shares of SI-BONE stock opened at $13.99 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a market cap of $594.98 million, a price-to-earnings ratio of -15.21 and a beta of 0.82. The stock’s 50-day moving average is $14.61 and its 200-day moving average is $14.67. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. Equities analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.